GlassScriptPhysician profile
Pankaj Jain
NPI 1215996301
$3,535.88
in general payments reported to CMS, 2019-2025
27 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $498 · 2021: $685 · 2022: $545 · 2023: $581 · 2024: $226 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $923.51 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $647.18 | 2019-2025 | Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.96 | 2019-2024 | Ofev |
| Mylan Specialty L.P. | $300.41 | 2019-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $154.62 | 2022-2024 | Dupixent |
| Philips North America LLC | $128.43 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Janssen Pharmaceuticals, INC | $127.75 | 2020-2022 | |
| Electromed, INC. | $80.62 | 2019-2021 | |
| Verona Pharma, INC. | $59.89 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $52.82 | 2022 | |
| Genzyme Corporation | $51.41 | 2021-2024 | |
| Pulmonx Corporation | $46.99 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Sunovion Pharmaceuticals INC. | $44.74 | 2019 | |
| Vanda Pharmaceuticals INC. | $44.69 | 2023 | Hetlioz |
| Merck Sharp & Dohme LLC | $43.17 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.24 | 2023 | Glassia |
| Harmony Biosciences LLC | $23.30 | 2024 | |
| Inspire Medical Systems, INC. | $21.82 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $21.78 | 2021 | |
| Inogen, INC. | $20.66 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Viatris Specialty LLC | $19.42 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $19.08 | 2021 | |
| Advanced Respiratory, INC | $15.96 | 2020 | |
| Pfizer INC. | $14.42 | 2020 | |
| Baxter Healthcare | $13.62 | 2023 | Hillrom - Life 2000 Ventilation System |
| Genentech USA, INC. | $12.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.